Denali Therapeutics Inc. Common Stock
Symbol: DNLI (NASDAQ)
14.65
▼ (-4.62%) -0.710
Company Description:
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Key Stats
- Today's Open: $15.34
- Today's High: $15.685
- Today's Low: $14.59
- Today's Volume: 1.67M
- Yesterday Close: $15.36
- Yesterday High: $15.62
- Yesterday Low: $14.7
- Yesterday Volume: 1.57M
- Last Min Volume: 0
- Last Min High: $14.65
- Last Min Low: $14.637
- Last Min VWAP: $0
Company Profile
- Name: Denali Therapeutics Inc. Common Stock
- Website: https://www.denalitherapeutics.com
- Listed Date: 2017-12-08
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001714899
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $2.27B
- Round Lot: 100
- Outstanding Shares: 146.21M
- Asset Type: CS
RECENT FILINGS FOR DNLI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-13 | 144 | View |
| 2025-08-12 | 144 | View |
| 2025-08-12 | 144 | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-08-07 | 4 | View |
| 2025-07-11 | 4 | View |
| 2025-07-09 | 144 | View |
| 2025-07-07 | 8-K | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 3 | View |
| 2025-06-05 | 3 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
Latest News on DNLI